当前位置: 首页 > 期刊 > 《中国医学创新》 > 2018年第17期
编号:13297223
微创穿刺引流联合尿激酶灌注治疗慢性硬膜下血肿患者的临床疗效观察(1)
http://www.100md.com 2018年6月15日 《中国医学创新》 2018年第17期
     【摘要】 目的:探討采用微创穿刺引流联合尿激酶灌注治疗慢性硬膜下血肿的临床综合疗效。方法:选取2014年7月-2017年6月本院收治的慢性硬膜下血肿患者119例为研究对象,按照不同临床治疗方式分成常规手术组(52例)和尿激酶手术组(67例)。常规手术组给予微创穿刺引流治疗,尿激酶手术组给予微创穿刺引流联合尿激酶灌注治疗。观察和比较两组临床指标、死亡率和复发情况。结果:尿激酶手术组的手术时间短于常规手术组,差异有统计学意义(t=17.846 8,P=0.000 0)。尿激酶手术组的拔管时间早于常规手术组,差异有统计学意义(t=6.262 2,P=0.000 0)。尿激酶手术组的住院时间短于常规手术组,差异有统计学意义(t=3.596 8,P=0.000 5)。尿激酶手术组死亡率为1.49%,与常规手术组的1.92%比较,差异无统计学意义(字2=0.032 8,P=0.856 2)。尿激酶手术组术后6个月内复发率为1.49%,显著低于常规手术组的11.54%,差异有统计学意义(字2=5.336 9,P=0.020 9)。结论:采用微创穿刺引流联合尿激酶灌注治疗慢性硬膜下血肿的临床综合疗效显著,术后复发率更低,是临床治疗慢性硬膜下血肿的可靠方案之一。
, 百拇医药
    【关键词】 微创穿刺引流; 尿激酶灌注; 慢性硬膜下血肿

    Observation the Clinical Efficacy of Minimally Invasive Puncture Drainage Combined with Ventricle Infusion of Urokinase in Treatment of Chronic Subdural Hematoma/XU Yicong,WANG Nengqiang,LIN Yunquan,et al.//Medical Innovation of China,2018,15(17):-126

    【Abstract】 Objective:To explore the clinical efficacy of minimally invasive puncture drainage combined with ventricle infusion of urokinase in the treatment of patients with chronic subdural hematoma.Method:A total of 119 cases with chronic subdural hematoma in our hospital from July 2014 to June 2017 were selected,they were divided into routine surgery groups(52 cases)and urokinase surgery group(67 cases)according to different clinical treatment methods.The routine surgery group was given with minimally invasive puncture drainage treatment.The urokinase surgery group was given with minimally invasive puncture drainage combined with ventricle infusion of urokinase treatment.The clinical indicators,death rates and recurrence were observed and compared between the two groups.Result:The time of operation in the urokinase surgery group was shorter than that in the routine surgery group,the difference was statistically significant(t=17.846 8,P=0.000 0).The time of extubation in the urokinase surgery group was sooner than that in the routine surgery group,the difference was statistically significant(t=6.262 2,P=0.000 0).The hospital stays in the urokinase surgery group was shorter than that in the routine surgery group,the difference was statistically significant(t=3.596 8,P=0.000 5).The mortality of urokinase group was 1.49%,compared with 1.92% in routine operation group,the difference was not statistically significant(字2=0.032 8,P=0.856 2).After surgery 6 months,the recurrence rate in the urokinase surgery group was 1.49%,which was lower than 11.54% in the routine surgery group ,the difference was statistically significant(字2=5.336 9,, 百拇医药(许奕聪 王能强 林运全 郭华强)
1 2 3下一页